Shopping Cart
- Remove All
Your shopping cart is currently empty
N3-PEG3-vc-PAB-MMAE, a drug-linker conjugate designed for Antibody-Drug Conjugates (ADC), features the integration of monomethyl auristatin E (MMAE), a tubulin inhibitor, via a 3-unit polyethylene glycol (PEG) linker. This compound demonstrates significant antitumor activity.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 100 mg | Inquiry | Backorder | |
| 500 mg | Inquiry | Backorder |
| Description | N3-PEG3-vc-PAB-MMAE, a drug-linker conjugate designed for Antibody-Drug Conjugates (ADC), features the integration of monomethyl auristatin E (MMAE), a tubulin inhibitor, via a 3-unit polyethylene glycol (PEG) linker. This compound demonstrates significant antitumor activity. |
| In vitro | Monomethyl auristatin E (MMAE; SGD-1010), a synthetic derivative of Dolastatin 10, acts as a potent mitotic inhibitor by blocking tubulin polymerization. It is widely used as the cytotoxic component in antibody-drug conjugates (ADCs) for treating various cancers. |
| Molecular Weight | 1352.66 |
| Formula | C67H109N13O16 |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.